These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 29530714)
61. Development of manufacturing method for rapidly disintegrating oral tablets using the crystalline transition of amorphous sucrose. Sugimoto M; Narisawa S; Matsubara K; Yoshino H; Nakano M; Handa T Int J Pharm; 2006 Aug; 320(1-2):71-8. PubMed ID: 16750604 [TBL] [Abstract][Full Text] [Related]
62. Preparation of orally disintegrating tablets with taste-masking function: masking effect in granules prepared with correctives using the dry granulation method and evaluation of tablets prepared using the taste-masked granules. Kawano Y; Ito A; Sasatsu M; Machida Y Yakugaku Zasshi; 2010 Jan; 130(1):81-6. PubMed ID: 20046070 [TBL] [Abstract][Full Text] [Related]
63. Preparation of Solifenacin Succinate Functional Particles Embedded in a Gelling-Swelling Layer (PEGS) and Their Formulation in Orally Disintegrating Tablets. Ijitsu S; Hoashi Y; Hori K; Okimoto K; Kai T; Yoshida M; Uchida T Chem Pharm Bull (Tokyo); 2021 May; 69(5):456-463. PubMed ID: 33627574 [TBL] [Abstract][Full Text] [Related]
64. Development of orally disintegrating tablets containing solid dispersion of a poorly soluble drug for enhanced dissolution: In-vitro optimization/in-vivo evaluation. Fouad SA; Malaak FA; El-Nabarawi MA; Abu Zeid K PLoS One; 2020; 15(12):e0244646. PubMed ID: 33382789 [TBL] [Abstract][Full Text] [Related]
65. Application of face centred central composite design to optimise compression force and tablet diameter for the formulation of mechanically strong and fast disintegrating orodispersible tablets. Pabari RM; Ramtoola Z Int J Pharm; 2012 Jul; 430(1-2):18-25. PubMed ID: 22465631 [TBL] [Abstract][Full Text] [Related]
66. PREPARATION AND CHARACTERIZATION OF ORALLY DISINTEGRATING LORATADINE TABLETS MANUFACTURED WITH CO-PROCESSED MIXTURES. Amelian A; Szekalska M; Wilczewska AZ; Basa A; Winnicka K Acta Pol Pharm; 2016; 73(2):453-60. PubMed ID: 27180438 [TBL] [Abstract][Full Text] [Related]
67. Design and evaluation of microwave-treated orally disintegrating tablets containing polymeric disintegrant and mannitol. Sano S; Iwao Y; Noguchi S; Kimura S; Itai S Int J Pharm; 2013 May; 448(1):132-41. PubMed ID: 23524122 [TBL] [Abstract][Full Text] [Related]
68. Early formulation development of CKD-519, a new CETP inhibitor, for phase 1 clinical study based on in vitro and in vivo evaluation. Park SJ; Thapa P; Seo HJ; Park ES; Hoon Jeong S Int J Pharm; 2018 Oct; 549(1-2):388-396. PubMed ID: 30107219 [TBL] [Abstract][Full Text] [Related]
69. Latent structure analysis of the process variables and pharmaceutical responses of an orally disintegrating tablet. Hayashi Y; Oshima E; Maeda J; Onuki Y; Obata Y; Takayama K Chem Pharm Bull (Tokyo); 2012; 60(11):1419-25. PubMed ID: 22878814 [TBL] [Abstract][Full Text] [Related]
70. Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants. Cheow WS; Ng ML; Kho K; Hadinoto K Int J Pharm; 2011 Feb; 404(1-2):289-300. PubMed ID: 21093560 [TBL] [Abstract][Full Text] [Related]
71. Ease of Taking and Palatability of Fixed-Dose Orally Disintegrating Mitiglinide/Voglibose Tablets. Sotoyama M; Uchida S; Kamiya C; Tanaka S; Kashiwagura Y; Hakamata A; Odagiri K; Inui N; Watanabe H; Namiki N Chem Pharm Bull (Tokyo); 2019; 67(6):540-545. PubMed ID: 31155559 [TBL] [Abstract][Full Text] [Related]
72. Formulation and evaluation of a montelukast sodium orally disintegrating tablet with a similar dissolution profile as the marketed product. Chen Y; Feng T; Li Y; Du B; Weng W Pharm Dev Technol; 2017 Mar; 22(2):168-172. PubMed ID: 26654222 [TBL] [Abstract][Full Text] [Related]
73. Orodispersible Carbamazepine/Hydroxypropyl-β-Cyclodextrin Tablets Obtained by Direct Compression with Five-in-One Co-processed Excipients. Conceição J; Adeoye O; Cabral-Marques H; Concheiro A; Alvarez-Lorenzo C; Sousa Lobo JM AAPS PharmSciTech; 2020 Jan; 21(2):39. PubMed ID: 31897724 [TBL] [Abstract][Full Text] [Related]
74. Application of the combinative particle size reduction technology H 42 to produce fast dissolving glibenclamide tablets. Salazar J; Müller RH; Möschwitzer JP Eur J Pharm Sci; 2013 Jul; 49(4):565-77. PubMed ID: 23587645 [TBL] [Abstract][Full Text] [Related]
75. Evaluation of two novel co-processed excipients for direct compression of orodispersible tablets and mini-tablets. Kokott M; Lura A; Breitkreutz J; Wiedey R Eur J Pharm Biopharm; 2021 Nov; 168():122-130. PubMed ID: 34474110 [TBL] [Abstract][Full Text] [Related]
76. Development and evaluation of orally disintegrating tablets (ODTs) containing Ibuprofen granules prepared by hot melt extrusion. Gryczke A; Schminke S; Maniruzzaman M; Beck J; Douroumis D Colloids Surf B Biointerfaces; 2011 Sep; 86(2):275-84. PubMed ID: 21592751 [TBL] [Abstract][Full Text] [Related]
77. Freeze drying of orally disintegrating tablets containing taste masked naproxen sodium granules in blisters. Stange U; Führling C; Gieseler H Pharm Dev Technol; 2015 Dec; 20(8):1018-1024. PubMed ID: 25220888 [TBL] [Abstract][Full Text] [Related]
78. Preparation and evaluation of fast-disintegrating effervescent tablets of glibenclamide. Jacob S; Shirwaikar A; Nair A Drug Dev Ind Pharm; 2009 Mar; 35(3):321-8. PubMed ID: 18821151 [TBL] [Abstract][Full Text] [Related]